TY - JOUR T1 - Heartbeat: Is there any effective therapy for heart failure with preserved ejection fraction? JF - Heart JO - Heart SP - 361 LP - 362 DO - 10.1136/heartjnl-2018-313040 VL - 104 IS - 5 AU - Catherine M Otto Y1 - 2018/03/01 UR - http://heart.bmj.com/content/104/5/361.abstract N2 - Heart failure with preserved ejection fraction (HFpEF) increasingly is recognised as a cause of disabling symptoms, yet we have little data to support medical therapy for this condition. In order to objectively assess the published data on drug therapy for HFpEF, Zheng and colleagues1 performed a systematic review and meta-analysis of 25 randomised controlled trials with a total of over 18 000 patients. This analysis showed that beta-blocker therapy was associated with lower all-cause mortality compared with placebo (RR: 0.78, 95% CI 0.65 to 0.94, P=0.008). Other studied therapies, including ACE inhibitors, aldosterone receptor blockers, and mineralocorticoid receptor antagonists were not associated with lower all-cause or cardiovascular mortality (figure 1).Figure 1 Pooled and individual estimates of relative risk (RR) and 95% CI of the primary outcome all-cause mortality for different therapies. Data are shown stratified by individual drug classes (beta-blockers, ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists and other … ER -